New Two-Pronged attack on cancer enters human testing
NCT ID NCT07266428
Summary
This early-stage study is testing a new drug called OTP-01 in adults with advanced solid tumors that have progressed after standard treatments. The main goals are to find the safest and most effective dose, understand how the body processes the drug, and see if it can shrink tumors. Participants receive the drug by IV infusion and undergo regular scans and blood tests to monitor their response and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Linear Clinical Research
RECRUITINGNedlands, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
South Texas Accelerated Research Therapeutics (START)
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
South Texas Accelerated Research Therapeutics (START) Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.